Fox Chase Cancer Center News

Study Finds Low Risk of Toxicity in Prostate Cancer Patients Treated With Hypofractionated Radiation Therapy

PHILADELPHIA (October 25, 2021)—A multi-institutional retrospective analysis conducted by researchers at Fox Chase Cancer Center has found that early stage prostate cancer patients treated with moderately hypofractionated intensity-modulated radiation therapy or proton beam radiation therapy had low risk of serious late genitourinary and gastrointestinal complications.

VIEW STORY